老年淋巴结阳性三阴性乳腺癌患者辅助紫杉烷联合蒽环类与紫杉烷类化疗方案的临床结局:SEER-Medicare研究
基于SEER-Medicare数据库纳入1106例66岁及以上淋巴结阳性三阴性乳腺癌女性,比较辅助化疗与否及含蒽环类联合紫杉烷(ATAX)与不含蒽环类紫杉烷(TAX)方案的结局。接受化疗者3年癌症特异性生存(CSS)和总生存(OS)均显著优于未化疗者;ATAX与TAX的3年CSS和OS相似;≥4枚阳性淋巴结者ATAX较TAX有结局更优的趋势,但未达统计学显著。
要点
- 1106例中767例(69.3%)接受辅助化疗,其中ATAX 364例(47.5%)、TAX 297例(39%)、其他方案106例(13.8%)。
- 任何化疗较未化疗的3年CSS为81.8% vs 71.4%、OS为70.7% vs 51.3%(P < 0.01)。
- ATAX与TAX的3年CSS 82.8% vs 83.7%(P = 0.80)、OS 74.2% vs 72.7%(P = 0.79),相似。
核心结论
- 在老年淋巴结阳性TNBC女性中,多数患者接受了辅助化疗,化疗与CSS和OS改善相关。
- 与TAX化疗相比,≥4枚阳性淋巴结患者接受ATAX有结局更优的趋势。
研究设计与样本
- 使用监测、流行病学和最终结果(SEER)-Medicare数据库的回顾性队列研究。
- 纳入2010年至2015年间诊断、年龄66岁及以上的淋巴结阳性TNBC女性1106例。
- 按辅助化疗方案(化疗 vs 未化疗;ATAX vs TAX)比较临床特征,采用逻辑回归估计OR及95%CI。
- 采用Kaplan-Meier曲线估计3年OS和CSS,Cox比例风险模型分析OS和CSS并控制患者和肿瘤特征。
主要发现
- 1106例中767例(69.3%)接受辅助化疗:ATAX 364/767(47.5%)、TAX 297/767(39%)、其他方案106/767(13.8%)。
- 接受ATAX而非TAX的独立预测因素包括更广泛的淋巴结受累(≥4)、年龄、婚姻/伴侣状态和非心脏合并症。
- 任何化疗 vs 未化疗的3年CSS为81.8% vs 71.4%,OS为70.7% vs 51.3%(P < 0.01)。
- ATAX vs TAX的3年CSS为82.8% vs 83.7%(P = 0.80),OS为74.2% vs 72.7%(P = 0.79)。
- ≥4枚阳性淋巴结者ATAX vs TAX的CSS风险比HR 0.66(95%CI: 0.36-1.23,P = 0.19),OS风险比HR 0.68(95%CI: 0.41-1.14,P = 0.14)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Triple-negative breast cancer (TNBC) is a subtype of breast cancer associated with an aggressive clinical course. Adjuvant chemotherapy reduces the risk of recurrence and improves survival in patients with node-positive TNBC. The benefit of anthracycline plus taxane (ATAX) regimens compared with non-anthracycline-containing, taxane-based regimens (TAX) in older women with node-positive TNBC is not well characterised. METHODS: Using the Surveillance, Epidemiology, and End Results-Medicare database, we identified 1106 women with node-positive TNBC diagnosed at age 66 years and older between 2010 and 2015. We compared patient clinical characteristics according to adjuvant chemotherapy regimen (chemotherapy versus no chemotherapy and ATAX versus TAX). Logistic regression was performed to estimate the odds ratios (OR) and 95% confidence intervals (CIs). Kaplan-Meier survival curves were generated to estimate 3-year overall survival (OS) and cancer-specific survival (CSS). Cox proportional hazard models were used to analyse OS and CSS while controlling for patient and tumour characteristics. RESULTS: Of the 1106 patients in our cohort, 767 (69.3%) received adjuvant chemotherapy with ATAX (364/767, 47.5%), TAX (297/767, 39%) or other regimens (106/767, 13.8%). Independent predictors of which patients were more likely to receive ATAX versus TAX included more extensive nodal involvement (≥4), age, marital/partner status and non-cardiac comorbidities. There was a statistically significant improvement in 3-year CSS (81.8% versus 71.4%) and OS (70.7% versus 51.3%) with the use of any chemotherapy in our cohort (P < 0.01). Three-year CSS and OS for patients who received ATAX versus TAX were similar at 82.8% versus 83.7% (P = 0.80) and 74.2% versus 72.7% (P = 0.79), respectively. There was a trend towards improved CSS and OS in patients with four or more positive lymph nodes who received ATAX versus TAX (hazard ratio 0.66, 95% CI: 0.36-1.23, P = 0.19 and hazard ratio 0.68, 95% CI: 0.41-1.14, P = 0.14, respectively). CONCLUSION: Among older women with node-positive TNBC, a majority of patients received adjuvant chemotherapy, which was associated with an improvement in CSS and OS. When compared with TAX chemotherapy, there was a trend towards better outcomes with ATAX for patients with ≥4 nodes.
引用
- Roy S, Lakritz S, Schreiber AR, et al. Clinical outcomes of adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: A SEER-Medicare study. Eur J Cancer. 2023. PMID: 36965330. doi:10.1016/j.ejca.2023.02.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。